Refractory B-Cell Non-Hodgkin Lymphoma Recruiting Phase 2 Trials for Fludarabine (DB01073)

IndicationStatusPhase
DBCOND0041833 (Refractory B-Cell Non-Hodgkin Lymphoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01434472High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaTreatment